Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 4/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368354 | 0.84 | CYP2A6 (0.56) | DRD2SLC6A4CHRNA7CRHBPCRHR2 | |
| SCHEMBL9347766 | 0.82 | CYP2A6 (0.55) | DRD2SLC6A4CHRNA7CRHBPCRHR2 | |
| SCHEMBL9347729 | 0.82 | CYP2A6 (0.55) | DRD2SLC6A4CHRNA7CRHBPCRHR2 | |
| SCHEMBL3789614 | 0.82 | CYP2A6 (0.58) | DRD2SLC6A4DRD3CHRNA7CRHBP | |
| SCHEMBL6692557 | 0.76 | SLC6A4 (0.50) | DRD2SLC6A4DRD3HTR1AKDM4E | |
| SCHEMBL91191 | 0.76 | CYP2A6 (0.62) | DRD2SLC6A4DRD3CHRNA7CRHBP | |
| SCHEMBL27760809 | 0.73 | HTR1A (0.46) | DRD2SLC6A4DRD3HTR1A | |
| SCHEMBL11779480 | 0.71 | SIGMAR1 (0.79) | — | |
| SCHEMBL6696545 | 0.70 | DRD2 (0.50) | DRD2SLC6A4HTR1ACYP2A6KDM4E | |
| SCHEMBL5708590 | 0.70 | SIGMAR1 (0.76) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004082686-A2 | USE OF COMPOUNDS WITH COMBINED 5-HT1A AND SSRI ACTIVITIES TO TREAT SEXUAL DYSFUNCTION | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | claimed |
| US-20040192730-A1 | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | US | claimed |
| WO-2004082686-A2 | USE OF COMPOUNDS WITH COMBINED 5-HT1A AND SSRI ACTIVITIES TO TREAT SEXUAL DYSFUNCTION | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040192730-A1 | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192730-A1 | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction | HTR5A, HTR1A, HTR3A | DRD2 84/4885SLC6A4 19/4885DRD3 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.